

## **Clinical Global Impression – Improvement**

Both subjects with a pre-synaptic mutation type were randomized to the amifampridine/placebo treatment arm. At Day 0 (Baseline) one subject reported a global improvement of 2 (much improved) and at Day 8 one subject reported a global improvement of 2 (much improved) and one subject reported a global improvement of 5 (minimally worse). At Day 21 (Baseline) one subject reported a global improvement of 2 (much improved) and one subject reported a global improvement of 3 (minimally improved) and at Day 29 both subjects reported a global improvement of 2 (much improved). For subjects with a post-synaptic mutation randomized to the amifampridine/placebo treatment arm, at Day 0 (Baseline) one subject reported a global improvement of 2 (much improved), one subject reported a global improvement of 3 (minimally improved), and one subject reported a global improvement of 4 (no change) while at Day 8 two subjects reported a global improvement of 3 (minimally improved) and four subjects reported a global improvement of 4 (no change). At Day 21 (Baseline) two subjects reported a global improvement of 2 (much improved), three subjects reported a global improvement of 3 (minimally improved), and one subject reported a global improvement of 4 (no change) while at Day 29 one subject reported a global improvement of 1 (very much improved), one subject reported a global improvement of 2 (much improved), and four subjects reported a global improvement of 4 (no change). For subjects with a post-synaptic mutation randomized to the placebo/amifampridine treatment arm, at Day 0 (Baseline) one subject reported a global improvement of 2 (much improved), two subjects reported a global improvement of 3 (minimally improved), and one subject reported a global improvement of 4 (no change) while at Day 8 one subject reported a global improvement of 2 (much improved), one subject reported a global improvement of 3 (minimally improved), three subjects reported a global improvement of 4 (no change), one subject reported a global improvement of 5 (minimally worse), and one subject reported a global improvement of 6 (much worse). At Day 21 (Baseline) one subject reported a global improvement of 1 (very much improved), two subjects reported a global improvement of 2 (much improved), two subjects reported a global improvement of 3 (minimally improved), and two subjects reported a global improvement of 4 (no change) while at Day 29 two subjects reported a global improvement of 2 (much improved), three subjects reported a global improvement of 3 (minimally improved), and two subjects reported a global improvement of 4 (no change). There were no statistically significant differences for CGI-I in subjects treated with amifampridine phosphate or placebo overall or by mutation type.